MGTA - Magenta Therapeutics announces expected 2021 highlights milestones

Magenta Therapeutics (MGTA) has announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023.MGTA-145: Three phase 2 clinical trials ongoing or planned. Initial data from the study are expected in mid-2021.MGTA-117: Completing GLP toxicology and GMP manufacturing of targeted conditioning antibody-drug conjugate, MGTA-117; plans to initiate clinical trial in acute myeloid leukemia and myelodysplastic syndromes in mid-2021.The company highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021.Ended 2020 with cash reserves of approximately $145 million that are expected to fund the current operating plan into 2023.These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 10:50 a.m. EST.KLDO is +12.7% to $12.0 Source: Press Release

For further details see:

Magenta Therapeutics announces expected 2021 highlights milestones